Hunan Warrant Pharmaceutical Co.,Ltd (SHA:688799)

SHA:688799 Ratios and Metrics

Market cap in millions CNY. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 26, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	5,825	6,264	3,928	4,591	2,986	3,862
Market Cap Growth	52.22%	59.46%	-14.43%	53.75%	-22.69%	-
Enterprise Value	5,882	6,320	3,696	4,184	2,376	3,094
Last Close Price	44.36	47.70	29.57	33.83	21.51	27.21
PE Ratio	24.11	25.94	23.91	21.72	16.33	24.02
PS Ratio	3.84	4.13	2.78	3.20	2.31	3.37
PB Ratio	2.92	3.14	2.15	2.60	1.80	2.61
P/TBV Ratio	3.19	3.43	2.48	2.84	2.01	2.72
P/FCF Ratio	-	-	-	42.24	125.46	170.68
P/OCF Ratio	-	-	27.62	21.41	19.18	33.66
EV/Sales Ratio	3.88	4.17	2.62	2.92	1.84	2.70
EV/EBITDA Ratio	18.73	20.13	17.77	15.85	11.01	16.27
EV/EBIT Ratio	23.99	25.78	26.57	20.62	14.23	19.85
EV/FCF Ratio	-	-	-	38.50	99.86	136.75
Debt / Equity Ratio	0.18	0.18	0.07	0.01	-	-
Debt / EBITDA Ratio	1.12	1.12	0.57	0.06	-	-
Debt / FCF Ratio	-	-	-	0.16	-	-
Net Debt / Equity Ratio	0.03	0.03	-0.30	-0.41	-0.42	-0.51
Net Debt / EBITDA Ratio	0.18	0.18	-2.59	-2.75	-3.23	-3.96
Net Debt / FCF Ratio	-	-	5.89	-6.69	-29.33	-33.30
Asset Turnover	-	-	0.61	0.69	0.68	0.84
Inventory Turnover	-	-	1.41	1.46	1.32	1.31
Quick Ratio	-	-	2.15	2.77	2.99	3.41
Current Ratio	-	-	3.42	4.01	4.23	4.65
Return on Equity (ROE)	12.66%	12.66%	7.73%	11.27%	11.05%	15.01%
Return on Assets (ROA)	-	-	3.75%	6.06%	5.48%	7.17%
Return on Invested Capital (ROIC)	11.77%	14.47%	10.28%	16.89%	17.61%	21.25%
Return on Capital Employed (ROCE)	-	-	6.80%	11.00%	9.70%	10.10%
Earnings Yield	4.15%	3.85%	4.18%	4.60%	6.12%	4.16%
FCF Yield	-	-	-2.33%	2.37%	0.80%	0.59%
Dividend Yield	0.97%	-	1.45%	1.90%	2.99%	1.84%
Payout Ratio	-	-	52.55%	39.96%	35.92%	-
Buyback Yield / Dilution	0.17%	0.17%	0.03%	-0.19%	-17.21%	-13.60%
Total Shareholder Return	1.14%	0.17%	1.48%	1.71%	-14.22%	-11.77%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.